Monoamine oxidases: The biochemistry of the proteins as targets in medicinal chemistry and drug discovery

Current Topics in Medicinal Chemistry

Volumn 12, Issue 20, 2012, Pages 2189-2209

  Ramsay, Rona R ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Antidepressants; Flavoprotein; Kinetic assays; Monoamine oxidases; Neurotransmitter levels; Redox state

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; NORADRENALIN; SEROTONIN;

COMBINATORIAL CHEMISTRY; DEGENERATIVE DISEASE; DRUG SYNTHESIS; HUMAN; NONHUMAN; REVIEW;

EID: 84874886072     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612805219978     Document Type: Review

References (286)

1. Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol., 2002, 9, 22-26.
2. http://www.who.int/mental_health/management/depression/definition/en/(1/4/12).
3. http://www.hcp.med.harvard.edu/ncs/ftpdir/NCSR_Lifetime_Prevalence_Estimates.pdf (1/4/12).
4. Tipton, K.F.; Singer, T.P. The radiochemical assay for monoamineoxidase activity problems and pitfalls. Biochem. Pharmacol., 1993, 46, 1311-1316.
5. Johnston, J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol., 1968, 17, 1285-1297.
6. Fowler, C.J.; Tipton, K.F. On the substrate specificities of 2 forms of monoamine oxidase. J. Pharm. Pharmacol., 1984, 36, 111-115.
7. Dostert, P.L.; Benedetti, M.S.; Tipton, K.F. Interactions of monoamine oxidase with substrates and inhibitors. Med. Res. Rev., 1989, 9, 45-89.
8. Tipton, K.F.; Boyce, S.; O'Sullivan, J.; Davey, G.P.; Healy, J. Monoamine oxidases: Certainties and uncertainties. Curr. Med. Chem., 2004, 11, 1965-1982.
9. Ramsay, R.R. Substrate regulation of monoamine oxidases. J Neural. Transm.-Suppl., 1998, 52, 139-147.
10. Weyler, W.; Hsu, Y.P.P.; Breakefield, X.O. Biochemistry and genetics of monoamine-oxidase. Pharmacol. Therapeut., 1990, 47, 391-417.
11. Westlund, K.N.; Denney, R.M.; Kochersperger, L.M.; Rose, R.M.; Abell, C.W. Distinct monoamine oxidase-A and oxidase-B populations in primate brain. Science, 1985, 230, 181-183.
12. Grimsby, J.; Lan, N.C.; Neve, R.; Chen, K.; Shih, J.C. Tissue distribution of human monoamine oxidase-A and oxidase-B messenger-RNA. J. Neurochem., 1990, 55, 1166-1169.
13. Cases, O.; Seif, I.; Grimsby, J.; Gaspar, P.; Chen, K.; Pournin, S.; Muller, U.; Aguet, M.; Babinet, C.; Shih, J.C.; Demaeyer, E. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science, 1995, 268, 1763-1766.
14. Shih, J.C.; Chen, K.; Ridd, M.J. Monoamine oxidase: From genes to behavior. Annu. Rev. Neurosci., 1999, 22, 197-217.
15. Bortolato, M.; Shih, J.C. Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Intl. Rev. Neurobiol., 2011, 100, 13-42.
16. Silverman, R.B.; Zieske, P.A.; Banik, G.M. A radical mechanism for monoamine-oxidase. Biochemistry, 1985, 24, 3372-3372.
17. Silverman, R.B. Radical Ideas About Monoamine-Oxidase. Accounts Chem. Res., 1995, 28, 335-342.
18. Kalgutkar, A.S.; Castagnoli, N.; Testa, B. Selective inhibitors of monoamine-oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Med. Res. Rev., 1995, 15, 325-388.
19. Edmondson, D.E. Structure-activity studies of the substrate-binding site in monoamine oxidase-B. Biochimie, 1995, 77, 643-650.
20. Wouters, J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr. Med. Chem., 1998, 5, 137-162.
21. Weyler, W.; Salach, J.I. Purification and properties of mitochondrial monoamine-oxidase type-A from human placenta. J. Biol. Chem., 1985, 260, 3199-3207.
22. Weyler, W.; Salach, J.I. Iron Content and Spectral Properties of Highly Purified Bovine Liver Monoamine-Oxidase. Arch. Biochem. Biophys., 1981, 212, 147-153.
23. Weyler, W.; Titlow, C.C.; Salach, J.I. Catalytically active Monoamine-Oxidase Type-A from human liver expressed in Saccharomyces-cerevisiae contains covalent FAD. Biochem. Biophys. Res. Commun., 1990, 173, 1205-1211.
24. Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E. High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr. Purif., 2000, 20, 334-345.
25. Li, M.; Hubalek, F.; Newton-Vinson, P.; Edmondson, D.E. Highlevel expression of human liver monoamine oxidase A in Pichia pastoris: Comparison with the enzyme expressed in Saccharomyces cerevisiae. Protein Expr. Purif., 2002, 24, 152-162.
26. Singer, T.P.; Ramsay, R.R. Flavoprotein structure and mechanism. 2. Monoamine Oxidases old friends hold many surprises. FASEB J., 1995, 9, 605-610.
27. Edmondson, D.E. Benzylamine analog binding studies as probes of the substrate sites of monoamine oxidases A and B. Drug Metab. Rev., 1999, 31, 235-245.
28. Edmondson, D.E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem., 2004, 11, 1983-1993.
29. Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, A. Molecular and mechanistic properties of the membrane-bound mitochondrial Monoamine Oxidases. Biochemistry, 2009, 48, 4220-4230.
30. Gillman, P.K. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J. Clin. Psychopharmacol., 2011, 31, 66-74.
31. Youdim, M.B.H.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006, 7, 295-309.
32. Weinreb, O.; Amit, T.; Riederer, P.; Youdim, M.B.H.; Mandel, S.A., Neuroprotective profile of the multitarget drug rasagiline in Parkinson's Disease. In Monoamine Oxidases and Their Inhibitors. Youdim, M.B.H., Ed.; Intl. Rev. Neurobiol. 2011, 100,127-149.
33. Schapira, A.H.V. Monoamine Oxidase B inhibitors for the treatment of Parkinson's Disease A review of symptomatic and potential disease-modifying effects. CNS Drugs, 2011, 25,1061-1071.
34. Bortolato, M.; Chen, K.; Shih, J.C. Monoamine oxidase inactiva tion: From pathophysiology to therapeutics. Adv. Drug Delivery Rev., 2008, 60,1527-1533.
35. Naoi, M.; Maruyama, W. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr. Pharmaceut. Des., 2010, 16, 2799-2817.
36. Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A. Targeting monoamine oxidases with multipotent ligands: An emerging strategy in the search of new drugs against neurodegenerative diseases. Curr. Med. Chem., 2011, 18, 4568-4587.
37. Van der Schyf, C.J.; Geldenhuys, W.J. Multimodal Drugs and Their Future for Alzheimer's and Parkinson's Disease. Intl. Rev. Neurobiol., 2011, 100, 107-125.
38. Hare, M.L.C. Tyramine oxidase: A new enzyme system in liver. Biochem. J., 1928, 62, 968-979.
39. http://www.chem.qmul.ac.uk/iubmb/enzyme/EC1/4/3/4.html (21/4/12).
40. Eisenhofer, G.; Kopin, I.J.; Goldstein, D.S. Catecholamine metabolism: A contemporary view with implications for physio logy and medicine. Pharmacol. Rev., 2004, 56, 331-349.
41. Finberg, J.P.M.; Gillman, K. Selective inhibitors of monoamine oxidase type B and the cheese effect. Intl. Rev. Neurobiol., 2011, 100, 169-190.
42. Youdim, M.B.H.; Buccafusco, J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 2005, 26, 27-35.
43. Bar-Am, O.; Weinreb, O.; Amit, T.; Youdim, M.B.H. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J. Neurochem., 2010, 112, 1131-1137.
44. Weinreb, O.; Bar-Am, O.; Prosolovich, K.; Amit, T.; Youdim, M.B.H. Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's Disease? Antiox. Redox Signal., 2011, 14, 767-775.
45. Amit, T.; Avramovich-Tirosh, Y.; Youdim, M.B.H.; Mandel, S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J., 2008, 22, 1296-1305.
46. Zheng, H.; Youdim, M.B.H.; Fridkin, M. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. Chem. Biol., 2010, 5, 603-610.
47. Geldenhuys, W.J.; Youdim, M.B.H.; Carroll, R.T.; Van der Schyf, C.J. The emergence of designed multiple ligands for neurodegenerative disorders. Prog. Neurobiol., 2011, 94, 347-359.
48. Liu, L.; Marcocci, L.; Wong, C.M.; Park, A.-M.; Suzuki, Y.J. Serotonin-mediated protein carbonylation in the right heart. Free Rad. Biol. Med., 2008, 45, 847-854.
49. Pena-Silva, R.A.; Miller, J.D.; Chu, Y.; Heistad, D.D. Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves. Am. J. Physiol.-Heart Circ. Physiol., 2009, 297, H1354-H1360.
50. Aluf, Y.; Vaya, J.; Khatib, S.; Finberg, J.P.M. Dopamine metabolism by monoamine oxidase is connected to oxidative stress in the rat brain. Movement Disorders, 2010, 25, S627-S627.
51. McRobb, F.M.; Capuano, B.; Crosby, I.T.; Chalmers, D.K.; Yuriev, E. Homology modeling and docking evaluation of aminergic G Protein-Coupled Receptors. J. Chem. Inf. Model., 2010, 50, 626-637.
52. Rasmussen, S.G.F.; Choi, H.-J.; Rosenbaum, D.M.; Kobilka, T.S.; Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V.R.P.; Sanishvili, R.; Fischetti, R.F.; Schertler, G.F.X.; Weis, W.I.; Kobilka, B.K. Crystal structure of the human beta(2) adrenergic Gprotein-coupled receptor. Nature, 2007, 450, 383-U384.
53. Carter, D.S.; Cai, H.-Y.; Lee, E.K.; Iyer, P.S.; Lucas, M.C.; Roetz, R.; Schoenfeld, R.C.; Weikert, R.J. 2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression. Bioorg. Med. Chem. Lett., 2010, 20, 3941-3945.
54. Colzi, A.; Dagostini, F.; Cesura, A.M.; Borroni, E.; Daprada, M. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus Evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. J. Pharmacol. Exp. Ther., 1993, 265, 103-111.
55. Sharp, T.; Gartside, S.E.; Umbers, V. Effects of co-administration of a monoamine oxidase inhibitor and a 5-HT1A receptor antagonist on 5-hydroxytryptamine cell firing and release. Eur. J. Pharmacol., 1997, 320, 15-19.
56. Berry M.D. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J. Neurochem., 2004, 90, 257-271.
57. Paterson, I.A.; Juorio, A.V.; Boulton, A.A. 2-Phenylethylamine a modulator of catecholamine transmission in the mammalian Central-Nervous-System. J. Neurochem., 1990, 55, 1827-1837.
58. Mousseau, D.D. Tryptamine a Metabolite of Tryptophan Implicated in Various Neuropsychiatric Disorders. Metab. Brain Dis., 1993, 8, 1-44.
59. Miller, G.M. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J. Neurosci., 2011, 116, 164-176.
60. Borowsky, B.; Adham, N.; Jones, K.A.; Raddatz, R.; Artymyshyn, R.; Ogozalek, K.L.; Durkin, M.M.; Lakhlani, P.P.; Bonini, J.A.; Pathirana, S.; Boyle, N.; Pu, X.S.; Kouranova, E.; Lichtblau, H.; Ochoa, F.Y.; Branchek, T.A.; Gerald, C. Trace amines: Identification of a family of mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. USA, 2001, 98, 8966-8971.
61. Wolinsky, T.D.; Swanson, C.J.; Smith, K.E.; Zhong, H.; Borowsky, B.; Seeman, P.; Branchek, T.; Gerald, C.P. The trace amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav., 2007, 6, 628-639.
62. Sotnikova, T.D.; Caron, M.G.; Gainetdinov, R.R. Trace AmineAssocaited Receptors as emerging therapeutic targets. Mol. Pharmacol., 2009, 76, 229-235.
63. Lindemann, L.; Hoener, M.C. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol. Sci., 2005, 26, 274-281.
64. Broadley, K.J. The vascular effects of trace amines and amphetamines. Pharmacol. Therapeut., 2010, 125, 363-375.
65. Zeng, C.; Armando, I.; Luo, Y.; Eisner, G.M.; Felder, R.A.; Jose, P.A. Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. Am. J. Physiol. Heart Circ. Physiol., 2008, 294, H551-H569.
66. Jose, P.A.; Eisner, G.M.; Felder, R.A. Regulation of blood pressure by dopamine receptors. Nephron, 2003, 95, 19-27.
67. Gershon, M.D.; Tack, J. The serotonin signaling system: From basic understanding to drug development-for functional GI disorders. Gastroenterol., 2007, 132, 397-414.
68. Auda, G.R.; Kirk, S.H.; Billett, M.A.; Billett, E.E. Localization of monoamine oxidase mRNA in human placenta. J. Histochem. Cytochem., 1998, 46, 1393-1400.
69. Egashira T. Studies on monoamine oxidase. XVIII. Enzymic properties of placental monoamine oxidase. Jap. J. Pharmacol., 1976, 26, 493-500.
70. Sivasubramaniam, S.D.; Finch, C.C.; Billett, M.A.; Baker, P.N.; Billett, E.E. Monoamine oxidase expression and activity in human placentae from pre-eclamptic and normotensive pregnancies. Placenta, 2002, 23,163-171.
71. Zhang, H.; Smith, G.N.; Liu, X.; Holden, J.J.A. Association of MAOA, 5-HTT, and NET promoter polymorphisms with gene expression and protein activity in human placentas. Physiol. Genet., 2010, 42, 85-92.
72. Blaschko, H. Amine oxidase and amine metabolism. Pharmacol. Rev., 1952, 4, 415-458.
73. Finberg, J.P.M.; Tenne, M. Relationship between tyramine potentiation and selective inhibition of monoamine-oxidase type-A and type-B in the rat vas-deferens. Brit. J. Pharmacol., 1982, 77, 13-21.
74. Boyer, E.W.; Shannon, M. The serotonin syndrome. New Engl. J. Med., 2005, 352, 1112-1120.
75. Gillman, P.K. A review of serotonin toxicity data: Implications for the mechanisms of antidepressant drug action. Biol. Psychiatry, 2006, 59, 1046-1051.
76. Bortolato, M.; Godar, S.C.; Davarian, S.; Chen, K.; Shih, J.C. Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice. Neuropsychopharm., 2009, 34, 2746-2757.
77. Brunner, H.G.; Nelen, M.; Breakefield, X.O.; Ropers, H.H.; Vanoost, B.A. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase-A. Science, 1993, 262, 578-580.
78. Alia-Klein, N.; Goldstein, R.Z.; Kriplani, A.; Logan, J.; Tomasi, D.; Williams, B.; Telang, F.; Shumay, E.; Biegon, A.; Craig, I.W.; Henn, F.; Wang, G.-J.; Volkow, N.D.; Fowler, J.S. Brain monoamine oxidase a activity predicts trait aggression. J. Neurosci., 2008, 28, 5099-5104.
79. Soliman, A.; Bagby, R.M.; Wilson, A.A.; Miler, L.; Clark, M.; Rusjan, P.; Sacher, J.; Houle, S.; Meyer, J.H. Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits. Pyschol. Med., 2011, 41, 1051-1060.
80. van Amsterdam, J.; Talhout, R.; Vleeming, W.; Opperhuizen, A. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. Life Sci., 2006, 79, 1969-1973.
81. Bortolato, M.; Shih, J.C. Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Intl. Rev. Neurobiol., 2011, 100, 13-42.
82. Meyer, J.H.; Ginovart, N.; Boovariwala, A.; Sagrati, S.; Hussey, D.; Garcia, A.; Young, T.; Praschak-Rieder, N.; Wilson, A.A.; Houle, S. Elevated monoamine oxidase A levels in the brain An explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry, 2006, 63, 1209-1216.
83. Curet, O.; Damoiseau-Ovens, G.; Sauvage, C.; Sontag, N.; Avenet, P.; Depoortere, H.; Caille, D.; Bergis, O.; Scatton, B. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. J. Affect. Disord., 1998, 51, 287-303.
84. Gillman, P.K. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J. Psychopharmacol., 2011, 25, 429-436.
85. Tipton, K.F. Inhibitors of monoamine oxidase and the pressor response to dietary amines. Vopr. Meditsinskoi Khimii, 1997, 43, 494-503.
86. Strolin Benedetti, M.; Tipton, K.F. Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics. J. Neural Transm., 1998, 52, 149-171.
87. Strolin Benedetti, M. FAD-dependent enzymes involved in the metabolic oxidation of xenobiotics. Ann. Pharmaceut. Francaises, 2011, 69, 45-52.
88. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog Synthesis. Science, 1983, 219, 979-980.
89. Langston, J.W. MPTP and Parkinsons-Disease. Trends Neurosci., 1985, 8, 79-83.
90. Chiba, K.; Trevor, A.; Castagnoli, N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine-oxidase. Biochem. Biophys. Res. Commun., 1984, 120, 574-578.
91. Chiba, K.; Trevor, A.J.; Castagnoli, N. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Commun., 1985, 128, 1228-1232.
92. Mytilineou, C.; Cohen, G.; Heikkila, R.E. 1-Methyl-4-phenyl pyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture. Neurosci. Lett., 1985, 57, 19-24.
93. Ramsay, R.R.; Singer, T.P. Energy-dependent uptake of N-methyl4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4phenyl-1,2,3,6tetrahydropyridine, by mitochondria. J. Biol. Chem., 1986, 261, 7585-7587.
94. Ramsay, R.R.; Kowal, A.T.; Johnson, M.K.; Salach, J.I.; Singer, T.P. The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch. Biochem. Biophys., 1987, 259, 645-649.
95. Nicklas, W.J.; Vyas, I.; Heikkila, R.E. Inhibition of NaADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydro pyridine. Life Sci., 1985, 36, 2503-2508.
96. Kopin, I.J.; Markey, S.P. MPTP toxicity Implications for research in Parkinsons-Disease. Ann. Rev. Neurosci., 1988, 11, 81-96.
97. Shimohama, S.; Sawada, H.; Kitamura, Y.; Taniguchi, T. Disease model: Parkinson's disease. Trends Molec. Med., 2003, 9, 360-365.
98. Heikkila, R.E.; Manzino, L.; Cabbat, F.S.; Duvoisin, R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4phenyl-1,2,5,6-tetrahydropyridine by monoamine-oxidase inhibi tors. Nature, 1984, 311, 467-469.
99. Krueger, M.J.; McKeown, K.; Ramsay, R.R.; Youngster, S.K.; Singer, T.P. Mechanism-based inactivation of monoamine oxidaseA and oxidase-B by tetrahydropyridines and dihydropyridines. Biochem. J., 1990, 268, 219-224.
100. Salach, J.I.; Singer, T.P.; Castagnoli, N.; Trevor, A. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase-A and Oxidase-B and suicide inactivation of the enzymes by MPTP. Biochem. Biophys. Res. Commun., 1984, 125, 831-835.
101. Kalgutkar, A.S.; Castagnoli, N. Synthesis of novel MPTP analogs as potential monoamine oxidaseB (MAO-B) inhibitors. J. Med. Chem., 1992, 35, 4165-4174.
102. Edmondson, D.E.; Bhattacharyya, A.K.; Walker, M.C. Spectral and kinetic studies of imine product formation in the oxidation of p(N,N-dimethylamino)benzylamine analogs by monoamine oxidaseB. Biochemistry, 1993, 32, 5196-5202.
103. Brenner-Lavie, H.; Klein, E.; Ben-Shachar, D. Mitochondrial complex I as a novel target for intraneuronal DA: Modulation of respiration in intact cells. Biochem. Pharmacol., 2009, 78, 85-95.
104. Burke, W.J.; Li, S.W.; Williams, E.A.; Nonneman, R.; Zahm, D.S. 3,4-dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res., 2003, 989, 205-213.
105. Burke, W.J.; Kumar, V.B.; Pandey, N.; Panneton, W.M.; Gan, Q.; Franko, M.W.; O'Dell, M.; Li, S.W.; Pan, Y.; Chung, H.D.; Galvin, J.E. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol., 2008, 115, 193-203.
106. Rees, J.N.; Florang, V.R.; Eckert, L.L.; Doorn, J.A. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, Is dependent on both the aldehyde and the catechol. Chem. Res. Toxicol., 2009, 22, 1256-1263.
107. Jinsmaa, Y.; Florang, V.R.; Rees, J.N.; Anderson, D.G.; Strack, S.; Doorn, J.A. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem. Res. Toxicol., 2009, 22, 835-841.
108. Anderson, D.G.; Mariappan, S.V.S.; Buettner, G.R.; Doorn, J.A. Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an orthoquinone. J. Biol. Chem., 2011, 286, 26978-26986.
109. Dardonville, C.; Rozas, I. Imidazoline binding sites and their ligands: An overview of the different chemical structures. Med. Res. Rev., 2004, 24, 639-661.
110. Taksande, B.G.; Kotagale, N.R.; Tripathi, S.J.; Ugale, R.R.; Chopde, C.T. Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacol., 2009, 57, 415-424.
111. Li, G.; Regunathan, S.; Barrow, C.J.; Eshraghi, J.; Cooper, R.; Reis, D.J. Agmatine an endogenous clonidine-displacing substance in the brain. Science, 1994, 263, 966-969.
112. Raddatz, R.; Parini, A.; Lanier, S.M. Imidazoline/guanidinium binding domains on Monoamine Oxidases Relationship to subtypes of imidazoline-binding proteins and tissue-specific interaction of imidazoline ligands with Monoamine-Oxidase-B. J. Biol. Chem., 1995, 270, 27961-27968.
113. Tesson, F.; Limon-Boulez, I.; Urban, P.; Puype, M.; Vandekerckhove, J.; Coupry, I.; Pompon, D.; Parini, A. Locali zation of I-2-imidazoline binding-sites on Monoamine Oxidases. J. Biol. Chem., 1995, 270, 9856-9861.
114. Remaury, A.; Ordener, C.; Shih, J.; Parini, A. Relationship between I-2 imidazoline binding sites and monoamine oxidase B in liver. Ann. N.Y. Acad. Sci, 1999, 881, 32-34.
115. Chapleo, C.B.; Myers, P.L. 22-(1,4-Benzodioxanyl) -2-imida zoline hydrochloride. Tetrahedron Lett., 1981, 22, 4839-4842.
116. Carpene, C.; Collon, P.; Remaury, A.; Cordi, A.; Hudson, A.; Nutt, D.; Lafontan, M. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I-2 sites. J. Pharmacol. Exp. Ther., 1995, 272, 681-688.
117. Gargalidis-Moudanos, C.; Pizzinat, N.; JavoyAgid, F.; Remaury, A.; Parini, A. I-2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease. Neurochem. Int., 1997, 30, 31-36.
118. Ozaita, A.; Olmos, G.; Boronat, M.A.; Lizcano, J.M.; Unzeta, M.; García-Sevilla, J.A. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I-2-imidazoline receptors in rat liver. Br. J. Pharmacol., 1997, 121, 901-912.
119. Jones, T.Z.E.; Giurato, L.; Guccione, S.; Ramsay, R.R. Interactions of imidazoline ligands with the active site of purified monoamine oxidase A. FEBS J., 2007, 274, 1567-1575.
120. Paterson, L.M.; Tyacke, R.J.; Robinson, E.S.J.; Nutt, D.J.; Hudson, A.L. In vitro and in vivo effect of BU99006 (5-isothiocyanato-2benzofuranyl-2-imidazoline) on I-2 binding in relation to MAO: Evidence for two distinct I-2 binding sites. Neuropharmacol., 2007, 52, 395-404.
121. McDonald, G.R.; Olivieri, A.; Ramsay, R.R.; Holt, A. On the formation and nature of the imidazoline I(2) binding site on human monoamine oxidase-B. Pharmacol. Res., 2010, 62, 475-488.
122. Bonivento, D.; Milczek, E.M.; McDonald, G.R.; Binda, C.; Holt, A.; Edmondson, D.E.; Mattevi, A. Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J. Biol. Chem., 2010, 285, 36849-36856.
123. García-Sevilla, J.A.; Sastre, M.; Escriba, P.V. Age-dependent increases of immunoreactive imidazoline receptors in the human brain Possible association of a 29/30-KDa protein with the I-2imidazoline receptor identified by H-3 idazoxan. Neurosci. Lett., 1995, 184, 133-136.
124. Ballesteros, J.; Maeztu, A.I.; Callado, L.F.; Gutierrez, M.; GarcíaSevilla, J.A.; Meana, J.J. I-2-Imidazoline receptors and monoamine oxidase B enzyme sites in human brain: covariation with age. Neurosci. Lett., 2000, 288, 135-138.
125. Gentili, F.; Cardinaletti, C.; Vesprini, C.; Ghelfi, F.; Farande, A.; Giannella, M.; Piergentili, A.; Quaglia, W.; Mattioli, L.; Perfumi, M.; Hudson, A.; Pigini, M. Novel ligands rationally designed for characterizing I(2)-imidazoline binding sites nature and functions. J. Med. Chem., 2008, 51, 5130-5134.
126. Murphy, D.L.; Redmond, D.E.; Garrick, N.; Baulu, J. Brain region differences and some characteristics of monoamine oxidase type A and B: Activities in the vervet monkey. Neurochem. Res., 1979, 4, 53-62.
127. Razygraev, A.V.; Arutjunyan, A.V. Monoamine oxidase activity in several structures of rat brain. Neurochem. J., 2007, 1, 204-207.
128. O'Carroll, A.M.; Anderson, M.C.; Tobbia, I.; Phillips, J.P.; Tipton, K.F. Determination of the absolute concentrations of monoamine oxidase-A and oxidase-B in human-tissues. Biochem. Pharmacol., 1989, 38, 901-905.
129. Westlund, K.N.; Denney, R.M.; Rose, R.M.; Abell, C.W. Localization of distinct monoamine-oxidase A and monoamine oxidase B cell populations in human brain-stem. Neurosci., 1988, 25, 439-456.
130. Nakamura, S.; Kawamata, T.; Yasuhara, O.; Akiguchi, I.; Kimura, J.; Kimura, H.; Kimura, T. The histochemical-demonstration of monoamine oxidase-containing neurons in the human hypotha lamus. Neurosci., 1991, 44, 457-463.
131. Saura, J.; Bleuel, Z.; Ulrich, J.; Mendelowitsch, A.; Chen, K.; Shih, J.C.; Malherbe, P.; DaPrada, M.; Richards, J.G. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience, 1996, 70, 755-774.
132. Westlund, K.N.; Krakower, T.J.; Kwan, S.W.; Abell, C.W. Intracellular-Distribution of Monoamine Oxidase-a in Selected Regions of Rat and Monkey Brain and Spinal-Cord. Brain Res., 1993, 612, 221-230.
133. Billett, E.E. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicol., 2004, 25, 139-148.
134. Tan, A.K.; Ramsay, R.R. Substrate-specific enhancement of the oxidative half-reaction of Monoamine-Oxidase. Biochemistry, 1993, 32, 2137-2143.
135. Schnaitman, C.; Erwin, V.G.; Greenawalt, J.W. The submito chondrial localization of monoamine oxidase. An enzymatic marker for the outer membrane of rat liver mitochondria. J. Cell Biol., 1967, 32, 719-735.
136. Houslay, M.D.; Tipton, K.F. Kinetic evaluation of monoamineoxidase activity in rat-liver mitochondrial outer membranes. Biochem. J., 1974, 139, 645-652.
137. Urban, P.; Andersen, J.K.; Hsu, H.P.P.; Pompon, D. Comparative membrane locations and activities of human monoamine oxidases expressed in yeast. FEBS Lett., 1991, 286, 142-146.
138. Rebrin, I.; Geha, R.M.; Chen, K.; Shih, J.C. Effects of carboxylterminal truncations on the activity and solubility of human monoamine oxidase B. J. Biol. Chem., 2001, 276, 29499-29506.
139. Cruz, F.; Edmondson, D.E. Kinetic properties of recombinant MAO-A on incorporation into phospholipid nanodisks. J. Neural Transm., 2007, 114, 699-702.
140. Saura, J.; Kettler, R.; Daprada, M.; Richards, J.G. Quantitative enzyme autoradiography with H-3 Ro 41-1049 and H-3 Ro 196327 in vitro Localization and abundance of MAO-A and MAOB in rat CNS, peripheral organs, and human brain. J. Neurosci., 1992, 12, 1977-1999.
141. Saura, J.; Andres, N.; Andrade, C.; Ojuel, J.; Eriksson, K.; Mahy, N. Biphasic and region-specific MAO-B response to aging in normal human brain. Neurobiol. Aging, 1997, 18, 497-507.
142. Sandler, M.; Reveley, M.A.; Glover, V. Human-platelet monoamine-oxidase activity in health and disease a review. J. Clin. Pathol., 1981, 34, 292-302.
143. Oreland, L.; Wiberg, A.; Asberg, M.; Traskman, L.; Sjostrand, L.; Thoren, P.; Bertilsson, L.; Tybring, G. Platelet MAO activity and monoamine metabolites in cerebrospinal-fluid in depressed and suicidal patients and in healthy controls. Psychiatry Res., 1981, 4, 21-29.
144. Lidberg, L.; Modin, I.; Oreland, L.; Tuck, J.R.; Gillner, A. Platelet monoamine-oxidase activity and psychopathy. Psychiatry Res., 1985, 16, 339-343.
145. Muck-Seler, D.; Presecki, P.; Mimica, N.; Mustapic, M.; Pivac, N.; Babic, A.; Nedic, G.; Folnegovic-Smalc, V. Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 1226-1231.
146. Anderson, M.C.; Hasan, F.; McCrodden, J.M.; Tipton, K.F. Monoamine oxidase inhibitors and the cheese effect. Neurochem. Res., 1993, 18, 1145-1149.
147. Fowler, J.S.; Logan, J.; Volkow, N.D.; Wang, G.J. Translational neuroimaging: Positron emission tomography studies of monoamine oxidase. Molec. Imag. Biol., 2005, 7, 377-387.
148. Fowler, J.S.; Volkow, N.D.; Wang, G.J.; Pappas, N.; Logan, J.; MacGregor, R.; Alexoff, D.; Shea, C.; Schlyer, D.; Wolf, A.P.; Warner, D.; Zezulkova, I.; Cilento, R. Inhibition of monoamine oxidase B in the brains of smokers. Nature, 1996, 379, 733-736.
149. Fowler, J.S.; Volkow, N.D.; Wang, G.J.; Pappas, N.; Logan, J.; Shea, C.; Alexoff, D.; MacGregor, R.R.; Schlyer, D.J.; Zezulkova, I.; Wolf, A.P. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. USA, 1996, 93, 14065-14069.
150. Sacher, J.; Houle, S.; Parkes, J.; Rusjan, P.; Sagrati, S.; Wilson, A.A.; Meyer, J.H. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [C-11]-harmine PET study. J. Psychiat. Neurosci., 2011, 36, 375-382.
151. Wang, J.; Edmondson, D.E. High-level expression and purification of rat monoamine oxidase A (MAO A) in Pichia pastoris: Comparison with human MAO A. Prot. Expr. Purif., 2010, 70, 211-217.
152. Wang, J.; Edmondson, D.E. (2)H Kinetic isotope effects and pH dependence of catalysis as mechanistic probes of rat monoamine oxidase A: Comparisons with the human enzyme. Biochemistry, 2011, 50, 7710-7717.
153. Fierro, A.; Osorio-Olivares, M.; Cassels, B.K.; Edmondson, D.E.; Sepulveda-Boza, S.; Reyes-Parada, M. Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphe tamine derivatives: Insights from molecular modeling studies. Bioorg. Med. Chem., 2007, 15, 5198-5206.
154. Geha, R.M.; Chen, K.; Shih, J.C. Phe(208) and Ile(199) in human monoamine oxidase A and B do not determine substrate and inhibitor specificities as in rat. J. Neurochem., 2000, 75, 1304-1309.
155. Finberg, J.P.M.; Youdim, M.B.H. Selective MAO-A and MAO-B inhibitors Their mechanism of action and pharmacology. Neuro pharmacol., 1983, 22, 441-446.
156. Krueger, M.J.; Mazouz, F.; Ramsay, R.R.; Milcent, R.; Singer, T.P. Dramatic species differences in the susceptibility of MonoamineOxidase-B to a group of powerful inhibitors. Biochem. Biophys. Res. Commun., 1995, 206, 556-562.
157. Garrick, N.A.; Murphy, D.L. Monoamine-Oxidase Type-A Differences in selectivity towards L-norepinephrine compared to serotonin. Biochem. Pharmacol., 1982, 31, 4061-4066.
158. Chen, K.; Wu, H.F.; Grimsby, J.; Shih, J.C. Cloning of a novel monoamine oxidase cDNA from trout liver. Mol. Pharmacol., 1994, 46, 1226-1233.
159. Setini, A.; Pierucci, F.; Senatori, O.; Nicotra, A. Molecular characterization of monoamine oxidase in zebrafish (Danio rerio). Comp. Biochem. Physiol. B-Biochem. Mol. Biol., 2005, 140, 153-161.
160. Anichtchik, O.; Sallinen, V.; Peitsaro, N.; Panula, P. Distinct structure and activity of monoamine oxidase in the brain of zebrafish (Danio rerio). J. Comp. Neurol., 2006, 498, 593-610.
161. Arslan, B.K.; Edmondson, D.E. Expression of zebrafish (Danio rerio) monoamine oxidase (MAO) in Pichia pastoris: Purification and comparison with human MAO A and MAO B. Prot. Expr. Purif., 2010, 70, 290-297.
162. Binda, C.; Aldeco, M.; Mattevi, A.; Edmondson, D.E. Interactions of monoamine oxidases with the antiepileptic drug zonisamide: Specificity of inhibition and structure of the human Monoamine Oxidase B complex. J Med Chem, 2011, 54, 909-912.
163. Aldeco, M.; Arslan, B.K.; Edmondson, D.E. Catalytic and inhibitor binding properties of zebrafish monoamine oxidase (zMAO): Comparisons with human MAO A and MAO B. Comp. Biochem. Physiol. B, 2011, 159, 78-83.
164. Chen, K. Organization of MAO A and MAO B promoters and regulation of gene expression. Neurotoxicology, 2004, 25, 31-36.
165. Sabol, S.Z.; Hu, S.; Hamer, D. A functional polymorphism in the monoamine oxidase A gene promoter. Human Genet., 1998, 103, 273-279.
166. Martin, N.G.; Whitfield, J.B.; Pang, D.; Kirk, K.M.; Heath, A.C. Association of monoamine oxidase (MAO) with smoking, alcohol dependence, and other measures of psychopathology and personality. Behav. Genet., 1999, 29, 363-363.
167. Oreland, L.; Hallman, J.; Damberg, M. Platelet MAO and personality Function and dysfunction. Curr. Med. Chem., 2004, 11, 2007-2016.
168. Prom-Wormley, E.C.; Eaves, L.J.; Foley, D.L.; Gardner, C.O.; Archer, K.J.; Wormley, B.K.; Maes, H.H.; Riley, B.P.; Silberg, J.L. Monoamine oxidase A and childhood adversity as risk factors for conduct disorder in females. Psychol. Med., 2009, 39, 579-590.
169. Barnett, J.H.; Xu, K.; Heron, J.; Goldman, D.; Jones, P.B. Cognitive effects of genetic variation in monoamine neuro transmitter systems: A population-based study of COMT, MAOA, and 5HTTLPR. Am. J. Med. Genet. Part B, 2011, 156B, 158-167.
170. Nicotra, A.; Pierucci, F.; Parvez, H.; Senatori, O. Monoamine oxidase expression during development and aging. Neurotoxicol., 2004, 25, 155-165.
171. Wang, C.C.; Borchert, A.; Ugun-Klusek, A.; Tang, L.Y.; Lui, W.T.; Chu, C.Y.; Billett, E.; Kuhn, H.; Ufer, C. Monoamine oxidase A expression Is vital for embryonic brain development by modulating developmental apoptosis. J. Biol. Chem., 2011, 286, 28322-28330.
172. Ou, X.M.; Chen, K.; Shih, J.C. Monoarnine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA, 2006, 103, 10923-10928.
173. Holschneider, D.P.; Chen, K.; Seif, I.; Shih, J.C. Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B. Brain Res. Bull., 2001, 56, 453-462.
174. Ma, J.C.; Ito, A. Tyrosine residues near the FAD binding site are critical for FAD binding and for the maintenance of the stable and active conformation of rat monoamine oxidase A. J. Biochem. (Tokyo), 2002, 131, 107-111.
175. Li, M.; Binda, C.; Mattevi, A.; Edmondson, D.E. Functional role of the aromatic cage in human monoamine oxidase B: Structures and catalytic properties of Tyr435 mutant proteins. Biochemistry, 2006, 45, 4775-4784.
176. Nandigama, R.K.; Miller, J.R.; Edmondson, D.E. Loss of serotonin oxidation as a component of the altered substrate specificity in the Y444F mutant of recombinant human liver MAO A. Biochemistry, 2001, 40, 14839-14846.
177. Hubalek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D.E. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J. Biol. Chem., 2005, 280, 15761-15766.
178. Wu, H.F.; Chen, K.; Shih, J.C. Site-directed mutagenesis of monoamine oxidase-A and oxidase-B Role of cysteines. Mol. Pharmacol., 1993, 43, 888-893.
179. Vintem, A.P.B.; Price, N.T.; Silverman, R.B.; Ramsay, R.R. Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines. Bioorg. Med. Chem., 2005, 13, 3487-3495.
180. Hubalek, F.; Pohl, J.; Edmondson, D.E. Structural comparison of human monoamine oxidases A and B Mass spectrometry monitoring of cysteine reactivities. J. Biol. Chem., 2003, 278, 28612-28618.
181. Kosenko, E.A.; Venediktova, N.I.; Kaminsky, Y.G. Calcium and ammonia stimulate monoamine oxidase a activity in brain mitochondria. Biol. Bull., 2003, 30, 449-452.
182. Cao, X.; Wei, Z.L.; Gabriel, G.G.; Li, X.M.; Mousseau, D.D. Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology. BMC Neurosci, 2007, 8, 73.
183. Samantaray, S.; Chandra, G.; Mohanakumar, K.P. Calcium channel agonist, (+/-)-Bay K8644, causes a transient increase in striatal monoamine oxidase activity in Balb/c mice. Neurosci. Lett., 2003, 342, 73-76.
184. Egashira, T.; Takayama, F.; Sakai, K. Effects of zinc ion on type A monoamine oxidase in monkey brain mitochondria. Biochem. Pharmacol., 2003, 65, 625-627.
185. Cao, X.; Rui, L.W.; Pennington, P.R.; Chlan-Fourney, J.; Jiang, Z.J.; Wei, Z.L.; Li, X.M.; Edmondson, D.E.; Mousseau, D.D. Serine 209 resides within a putative p38(MAPK) consensus motif and regulates monoamine oxidase-A activity. J. Neurochem., 2009, 111, 101-110.
186. Ramsay, R.R.; Armstrong, S., Calcium ions alter monoamine oxidase A activity In Flavins and Flavoproteins 2011. S, M., Ed.; Flavins and Flavoproteins 2011 in press.
187. Pennington, P.R.; Wei, Z.; Rui, L.; Doig, J.A.; Graham, B.; Kuski, K.; Gabriel, G.G.; Mousseau, D.D. Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro. J. Neural Transm., 2011, 118, 987-995.
188. Wei, Z.; Gabriel, G.G.; Rui, L.; Cao, X.; Pennington, P.R.; ChlanFourney, J.; Nazarali, A.J.; Baker, G.B.; Mousseau, D.D. Monoamine Oxidase-A Physically Interacts with Presenilin1(M146V) in the Mouse Cortex. J. Alz. Dis., 2012, 28, 403-422.
189. Ma, J.C.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J. Mol. Biol., 2004, 338, 103-114.
190. Weyler, W. Functional expression of C-terminally truncated human monoamine-oxidase type-A in Saccharomyces-cerevisiae. J. Neural Transm.-Suppl., 1994, 41, 3-15.
191. Chen, K.; Wu, H.F.; Shih, J.C. Influence of C terminus on monoamine oxidase A and B catalytic activity. J. Neurochem., 1996, 66, 797-803.
192. Newton-Vinson, P.; Edmondson, D.E. Properties of C-terminal truncated mutants of monoamine oxidase B. FASEB J., 2001, 15, A524.
193. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D.E.; Mattevi, A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. USA, 2003, 100, 9750-9755.
194. Binda, C.; Hubalek, F.; Li, M.; Castagnoli, N.; Edmondson, D.E.; Mattevi, A. Structure of the human mitochondrial monoamine oxidase B New chemical implications for neuroprotectant drug design. Neurology, 2006, 67, S5-S7.
195. McDonald, G.R.; Hudson, A.L.; Dunn, S.M.J.; You, H.T.; Baker, G.B.; Whittal, R.M.; Martin, J.W.; Jha, A.; Edmondson, D.E.; Holt, A. Bioactive contaminants leach from disposable laboratory plasticware. Science, 2008, 322, 917-917.
196. Binda, C.; Hubalek, F.; Li, M.; Edmondson, D.E.; Mattevi, A. Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Lett., 2004, 564, 225-228.
197. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. USA, 2005, 102, 12684-12689.
198. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D.E.; Mattevi, A. Binding of rasagiline-related inhibitors to human monoamine oxidases. a kinetic and crystallographic analysis. J. Med. Chem., 2005, 48, 8148-8154.
199. Edmondson, D.E.; Binda, C.; Mattevi, A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys., 2007, 464, 269-276.
200. Binda, C.; Mattevi, A.; Edmondson, D.E. Structural properties of human monoamine oxidases A and B. Intl. Rev. Neurobiol., 2012, 100, 1-11.
201. Moureau, F.; Wouters, J.; Vercauteren, D.P.; Collin, S.; Evrard, G.; Durant, F.; Ducrey, F.; Koenig, J.J.; Jarreau, F.X. A reversible monoamine-oxidase inhibitor, Toloxatone spectrophotometric and molecular-orbital studies of the interaction with flavin adeninedinucleotide (FAD). Eur. J. Med. Chem., 1994, 29, 269-277.
202. Fraaije, M.W.; Mattevi, A. Flavoenzymes: diverse catalysts with recurrent features. Trends Biochem. Sci., 2000, 25, 126-132.
203. Binda, C.; Mattevi, A.; Edmondson, D.E. Structure-function relationships in flavoenzyme-dependent amine oxidations. A comparison of polyamine oxidase and monoamine oxidase. J. Biol. Chem., 2002, 277, 23973-23976.
204. Erdem, S.S.; Karahan, O.; Yildiz, I.; Yelekci, K. A computational study on the amine-oxidation mechanism of monoamine oxidase: Insight into the polar nucleophilic mechanism. Org. Biomol. Chem., 2006, 4, 646-658.
205. Borstnar, R.; Repic, M.; Krzan, M.; Mavri, J.; Vianello, R. Irreversible inhibition of monoamine oxidase B by the antiparkin sonian medicines rasagiline and selegiline: A computational study. Eur. J. Org. Chem., 2011, 6419-6433.
206. Hynson, R.M.G.; Kelly, S.M.; Price, N.C.; Ramsay, R.R. Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim. Biophys. Acta-Gen. Subj., 2004, 1672, 60-66.
207. Ramsay, R.R.; Sablin, S.O.; Singer, T.P. Redox properties of the flavin cofactor of monoamine oxidases A and B and their relationship to the kinetic mechanism. Prog. Brain Res., 1995, 106, 33-39.
208. Edmondson, D.E.; Binda, C.; Mattevi, A. The FAD binding sites of human monoamine oxidases A and B. Neurotoxicol., 2004, 25, 6372.
209. Fitzpatrick, P.F. Oxidation of amines by flavoproteins. Arch. Biochem. Biophys., 2010, 493, 13-25.
210. Kay, C.W.M.; El Mkami, H.; Molla, G.; Pollegioni, L.; Ramsay, R.R. Characterization of the covalently bound anionic flavin radical in monoamine oxidase a by electron paramagnetic resonance. J. Am. Chem. Soc., 2007, 129, 16091-16097.
211. Silverman, R.B.; Lu, X.L. Evidence against a nucleophilic mechanism for monoamine oxidase-catalyzed amine oxidation. J. Am. Chem. Soc., 1994, 116, 4129-4130.
212. Silverman, R.B. Radical thoughts about the life of MAO. Prog. Brain Res., 1995, 106, 23-31.
213. Lu, X.; Rodriguez, M.; Ji, H.; Silverman, R.B.; Vintém, A.-P.B.; Ramsay, R.R., Irreversible inactivation of mitochondrial mono amine oxidases. In Flavins and Flavoproteins 2002. Chapman, S.K.; Perham, R.N.; Scrutton, N.S., Ed.; Rudolf Weber; 2002, 817-830.
214. MacMillar, S.; Edmondson, D.E.; Matsson, O. Nitrogen kinetic isotope effects for the Monoamine Oxidase B-catalyzed oxidation of benzylamine and (1,1-(2)H(2))benzylamine: nitrogen rehybridi zation and CH bond cleavage are not concerted. J. Am. Chem. Soc., 2011, 133, 12319-12321.
215. Rigby, S.E.J.; Hynson, R.M.G.; Ramsay, R.R.; Munro, A.W.; Scrutton, N.S. A stable tyrosyl radical in monoamine oxidase A. J. Biol. Chem., 2005, 280, 4627-4631.
216. Dunn, R.V.; Munro, A.W.; Turner, N.J.; Rigby, S.E.J.; Scrutton, N.S. Tyrosyl radical formation and propagation in flavin dependent monoamine oxidases. Chembiochem, 2010, 11, 1228-1231.
217. Weissbach, H.; Smith, T.E.; Daly, J.W.; Witkop, B.; Udenfriend, S. A rapid spectrophotometric assay of Monoamine Oxidase based on the rate of disappearance of kynuramine. J. Biol. Chem, 1960, 235, 1160-1163.
218. Youngster, S.K.; McKeown, K.A.; Jin, Y.Z.; Ramsay, R.R.; Heikkila, R.E.; Singer, T.P. Oxidation of analogs of 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase-A and oxidase-B and the inhibition of monoamine oxidases by the oxidation products. J. Neurochem., 1989, 53, 1837-1842.
219. Kalgutkar, A.S.; Castagnoli, K.; Hall, A.; Castagnoli, N. Novel 4(aryloxy)tetrahydropyridine analogs of MPTP as monoamineoxidase-A and monoamine-oxidase-B substrates. J. Med. Chem., 1994, 37, 944-949.
220. Williams, C.H.; Lawson, J.; Backwell, F.R.C. Oxidation of 3amino-1-phenylprop-1-enes by monoamine oxidase and their use in a continuous assay of the enzyme. Biochem. J., 1988, 256, 911-915.
221. Yu, P.H.; Bailey, B.A.; Durden, D.A. High-performance liquid chromatography of aldehydes and acids formed in monoamine oxidase-catalyzed reactions. Anal. Biochem., 1986, 152, 160-166.
222. Peng, L.; Zhang, G.; Zhang, D.; Wang, Y.; Zhu, D. A direct continuous fluorometric turn-on assay for monoamine oxidase B and its inhibitor-screening based on the abnormal fluorescent behavior of silole. Analyst, 2010, 135, 1779-1784.
223. Holt, A.; Palcic, M.M. A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes. Nat. Protocols, 2006, 1, 498-2505.
224. Zhou, M.J.; PanchukVoloshina, N. A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. Anal. Biochem., 1997, 253, 169-174.
225. Castillo, J.; Hung, J.; Rodriguez, M.; Bastidas, E.; Laboren, I.; Jaimes, A. LED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivation. Anal. Biochem., 2005, 343, 293-298.
226. Forneris, F.; Orru, R.; Bonivento, D.; Chiarelli, L.R.; Mattevi, A. ThermoFAD, a Thermofluor((R))-adapted flavin ad hoc detection system for protein folding and ligand binding. FEBS J., 2009, 276, 2833-2840.
227. Cesura, A.M.; Galva, M.D.; Imhof, R.; Daprada, M. Binding of H3 Ro 16-6491, a reversible inhibitor of monoamine oxidase type-B, to human brain mitochondria and platelet membranes. J. Neurochem., 1987, 48, 170-176.
228. May, T.; Pawlik, M.; Rommelspacher, H. [H-3] Harman binding experiments. 2. Regional and subcellular-distribution of specific [H-3] harman binding and monoamine-oxidase subtype-A and subtype-B activity in marmoset and rat. J. Neurochem., 1991, 56, 500-508.
229. Fowler, J.S.; Macgregor, R.R.; Wolf, A.P.; Arnett, C.D.; Dewey, S.L.; Schlyer, D.; Christman, D.; Logan, J.; Smith, M.; Sachs, H.; Aquilonius, S.M.; Bjurling, P.; Halldin, C.; Hartvig, P.; Leenders, K.L.; Lundqvist, H.; Oreland, L.; Stalnacke, C.G.; Langstrom, B. Mapping human-brain monoamine oxidase-A and oxidase-B with C-11 labeled suicide inactivators and PET. Science, 1987, 235, 481-485.
230. Fowler, J.S.; Logan, J.; Wang, G.J.; Volkow, N.D.; Telang, F.; Zhu, W.; Franceschi, D.; Pappas, N.; Ferrieri, R.; Shea, C.; Garza, V.; Xu, Y.W.; Schlyer, D.; Gatley, S.J.; Ding, Y.S.; Alexoff, D.; Warner, D.; Netusil, N.; Carter, P.; Jayne, M.; King, P.; Vaska, P. Low monoamine oxidase B in peripheral organs in smokers. Proc. Natl. Acad. Sci. USA, 2003, 100, 11600-11605.
231. Valette, H.; Bottlaender, M.; Dolle, F.; Coulon, C.; Ottaviani, M.; Syrota, A. Acute inhibition of cardiac monoamine oxidase a after tobacco smoke inhalation: Validation study of [C-11] befloxatone in rats followed by a positron emission tomography application in baboons. J. Pharmacol. Exp. Ther., 2005, 314, 431-436.
232. Takano, A. The Application of PET Technique for the Develop ment and Evaluation of Novel Antipsychotics. Curr. Pharm. Des., 2010, 16, 371-377.
233. Sacher, J.; Rabiner, E.A.; Clark, M.; Rusjan, P.; Soliman, A.; Boskovic, R.; Kish, S.J.; Awilson, A.; Houle, S.; Meyer, J.H. Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [C-11]-harmine positron emission tomography study. J. Cereb. Blood Flow Metab., 2012, 32, 443-446.
234. Nag, S.; Lehmann, L.; Heinrich, T.; Thiele, A.; Kettschau, G.; Nakao, R.; Gulyas, B.; Halldin, C. Synthesis of three novel fluorine-18 labeled analogues of L-deprenyl for Positron Emission Tomography (PET) studies of Monoamine Oxidase B (MAO-B). J. Med. Chem., 2011, 54, 7023-7029.
235. Morrison, J.F. Kinetics of reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta, 1968, 185, 269-286.
236. Tipton, K.F.; Davey, G.P.; McDonald, A.G. Kinetic behavior and reversible inhibition of monoamine oxidases enzymes that many want dead. Intl. Rev. Neurobiol., 2011, 100, 43-64.
237. McEwen, C.M., Jr.; Sasaki, G.; Lenz, W.R., Jr. Human liver mitochondrial monoamine oxidase. I. Kinetic studies of model interactions. J. Biol. Chem., 1968, 243, 5217-5225.
238. Jones, T.Z.E.; Balsa, D.; Unzeta, M.; Ramsay, R.R. Variations in activity and inhibition with pH: the protonated amine is the substrate for monoamine oxidase, but uncharged inhibitors bind better. J. Neural Transm., 2007, 114, 707-712.
239. Dunn, R.V.; Marshall, K.R.; Munro, A.W.; Scrutton, N.S. The pH dependence of kinetic isotope effects in monoamine oxidase A indicates stabilization of the neutral amine in the enzyme-substrate complex. FEBS J., 2008, 275, 3850-3858.
240. Fowler, C.J.; Oreland, L. The nature of the substrate-selective interaction between rat-liver mitochondrial monoamine-oxidase and oxygen. Biochem. Pharmacol., 1980, 29, 2225-2233.
241. Ramsay, R.R. Kinetic mechanism of Monoamine Oxidase-A. Biochemistry, 1991, 30, 4624-4629.
242. Walker, M.C.; Edmondson, D.E. Structure-activity-relationships in the oxidation of benzylamine analogs by bovine liver mitochondrial monoamineoxidase-B. Biochemistry, 1994, 33, 7088-7098.
243. Husain, M.; Edmondson, D.E.; Singer, T.P. Kinetic-studies on the catalytic mechanism of liver MonoamineOxidase. Biochemistry, 1982, 21, 595-600.
244. Miller, J.R.; Edmondson, D.E. Structure-activity relationships in the oxidation of parasubstituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry, 1999, 38, 13670-13683.
245. Nandigama, R.K.; Edmondson, D.E. Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry, 2000, 39,15258-15265.
246. Scrutton, N.S. Chemical aspects of amine oxidation by flavoprotein enzymes. Nat. Prod. Reports, 2004, 21, 722-730.
247. Ramsay, R.R.; Koerber, S.C.; Singer, T.P. Stopped-flow studies on the mechanism of oxidation of N-methyl4-phenyltetrahydro pyridine by bovine liver Monoamine Oxidase-B. Biochemistry, 1987, 26, 3045-3050.
248. Jonsson, T.; Edmondson, D.E.; Klinman, J.P. Hydrogen tunneling in the flavoenzyme monoamine-oxidase-B. Biochemistry, 1994, 33, 14871-14878.
249. Hay, S.; Pudney, C.R.; Scrutton, N.S. Structural and mechanistic aspects of flavoproteins: probes of hydrogen tunnelling. FEBS J., 2009, 276, 3930-3941.
250. Ramsay, R.R.; Olivieri, A.; Holt, A. An improved approach to steady-state analysis of monoamine oxidases. J. Neural Transm., 2011, 118, 1003-1019.
251. Pearce, L.B.; Roth, J.A. Human-brain Monoamine-Oxidase type-B Mechanism of deamination as probed by steady-state methods. Biochemistry, 1985, 24, 1821-1826.
252. Tipton, K.F. Monoamine-Oxidase Inhibition. Biochem. Soc. Trans., 1994, 22, 764-768.
253. Kitz, R.; Wilson, I.B. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem., 1962, 237, 3245-3249.
254. Ding, C.Z.; Silverman, R.B. Selective inactivation of monoamine oxidase-B by aminoethyl 3chlorobenzyl ether. Bioorg. Med. Chem. Lett., 1993, 3, 2077-2078.
255. Curet, O.; Damoiseau, G.; Aubin, N.; Sontag, N.; Rovei, V.; Jarreau, F.X. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor.1. Biochemical profile. J. Phar macol. Exp. Ther., 1996, 277, 253-264.
256. Kim, H.; Sablin, S.O.; Ramsay, R.R. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch. Biochem. Biophys., 1997, 337, 137-142.
257. May, T.; Rommelspacher, H.; Pawlik, M. [H-3] Harman binding experiments. 1. A reversible and selective radioligand for mono amine-oxidase subtype-A in the CNS of the rat. J. Neurochem., 1991, 56, 490-499.
258. Ramsay, R.R.; Dunford, C.; Gillman, P.K. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Brit. J. Pharmacol., 2007, 152, 946-951.
259. Petzer, A.; Harvey, B.H.; Wegener, G.; Petzer, J.P., Azure B, A metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol. Appl. Pharmacol., 2011, 258, 403-409.
260. Reck, F.; Zhou, F.; Girardot, M.; Kern, G.; Eyermann, C.J.; Hales, N.J.; Ramsay, R.R.; Gravestock, M.B. Identification of 4substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J. Med. Chem., 2005, 48, 499-506.
261. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N,N '-bis[2-oxo-2Hbenzopyran]-3-carboxamides. Bioorg. Med. Chem. Lett., 2006, 16, 4135-4140.
262. La Regina, G.; Silvestri, R.; Artico, M.; Lavecchia, A.; Novellino, E.; Befani, O.; Turini, P.; Agostinelli, E. New pyrrole inhibitors of monoamine oxidase: Synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J. Med. Chem., 2007, 50, 922-931.
263. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Chalcones: a valid scaffold for monoamine oxidases inhibitors. J. Med. Chem., 2009, 52,2818-2824.
264. Van der Walt, E.M.; Milczek, E.M.; Malan, S.F.; Edmondson, D.E.; Castagnoli, N., Jr.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg. Med. Chem. Lett., 2009, 19, 2509-2513.
265. Shi, L.; Yang, Y.; Li, Z.-L.; Zhu, Z.-W.; Liu, C.-H.; Zhu, H.-L. Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg. Med. Chem., 2010, 18, 1659-1664.
266. Manley-King, C.I.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamine oxidase by C5-substituted phthalimide analogues. Bioorg. Med. Chem., 2011, 19, 4829-4840.
267. Legoabe, L.; Kruger, J.; Petzer, A.; Bergh, J.J.; Petzer, J.P. Monoamine oxidase inhibition by selected anilide derivatives. Eur. J. Med. Chem., 2011, 46, 5162-5174.
268. Jones, T.Z.E.; Fleming, P.; Eyermann, C.J.; Gravestock, M.B.; Ramsay, R.R. Orientation of oxazolidinones in the active site of monoamine oxidase. Biochem. Pharmacol., 2005, 70, 407-416.
269. Upadhyay, A.K.; Edmondson, D.E. Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B. Biochemistry, 2009, 48, 3928-3935.
270. Chuang, H.Y.K.; Patek, D.R.; Hellerma, L. Mitochondrial monoamine oxidase inactivation by pargyline adduct formation. J. Biol. Chem., 1974, 249, 2381-2384.
271. Gartner, B.; Hemmerich, P.; Zeller, E.A. Structure of flavin adducts with acetylenic substrates Chemistry of monoamine-oxidase and lactate oxidase Inhibition. Eur. J. Biochem., 1976, 63, 211-221.
272. Zeller, E.A.; Hemmerich, P.; Gartner, B. 4a,5-Cycloaddition reactions of acetylenic-compounds at flavoquinone nucleus as mechanisms of Flavoprotein inhibitions. Z. Naturforsch. B, 1972, B 27, 1050-1052.
273. Williams, C.H.; Lawson, J. Monoamine oxidase-III. Further studies of inhibition by propargylamines. Biochem. Pharmacol., 1975, 23, 615-628.
274. Maycock, A.L.; Abeles, R.H.; Salach, J.I.; Singer, T.P. Structure of covalent adduct formed by interaction of 3-dimethylamino-1propyne and flavin of mitochondrial amine oxidase. Biochemistry, 1976, 15, 114-125.
275. Milczek, E.M.; Bonivento, D.; Binda, C.; Mattevi, A.; McDonald, I.A.; Edmondson, D.E. Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B. J. Med. Chem., 2008, 51, 8019-8026.
276. Zeller, E.A.; Sarkar, S. Amine oxidases. XIX. Inhibition of monoamine oxidase by phenylcyclopropylamines and iproniazid. J. Biol. Chem., 1962, 237, 2333-2336.
277. Paech, C.; Salach, J.I.; Singer, T.P. Suicide inactivation of monoamine-oxidase by trans-phenylcyclopropylamine. J. Biol. Chem., 1980, 255, 2700-2704.
278. Silverman, R.B. Mechanism of inactivation of monoamine-oxidase by trans-2-phenylcyclopropylamine and the structure of the enzyme-inactivator adduct. J. Biol. Chem., 1983, 258, 4766-4769.
279. Silverman, R.B.; Hiebert, C.K. Inactivation of monoamine oxidaseA by the monoamine oxidase-B inactivators 1-phenylcyclo propylamine, 1benzylcyclopropylamine, and N-cyclopropylalphamethylbenzylamine. Biochemistry, 1988, 27, 8448-8453.
280. Mitchell, D.J.; Nikolic, D.; Rivera, E.; Sablin, S.O.; Choi, S.; van Breemen, R.B.; Singer, T.P.; Silverman, R.B. Spectrometric evidence for the flavin-1-phenylcyclopropylamine inactivator adduct with monoamine oxidase N. Biochemistry, 2001, 40, 5447-5456.
281. Nagy, J.; Kenney, W.C.; Singer, T.P. Reaction of phenylhydrazine with trimethylamine dehydrogenase and with free flavins. J. Biol. Chem., 1979, 254, 2684-2688.
282. Binda, C.; Wang, J.; Li, M.; Hubalek, F.; Mattevi, A.; Edmondson, D.E. Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B. Biochemistry, 2008, 47, 5616-5625.
283. Mimasu, S.; Sengoku, T.; Fukuzawa, S.; Umehara, T.; Yokoyama, S. Crystal structure of histone demethylase LSD1 and tranylcyp romine at 2.25 angstrom. Biochem. Biophys. Res. Commun., 2008, 366, 15-22.
284. Silverman, R.B.; Zieske, P.A. 1-Benzylcyclopropylamine and 1(phenylcyclopropyl)methylamine an inactivator and a substrate of monoamine-oxidase. J. Med. Chem., 1985, 28, 1953-1957.
285. Zhong, B.Y.; Silverman, R.B. Identification of the active site cysteine in bovine liver monoamine oxidase B. J. Am. Chem. Soc., 1997, 119, 6690-6691.
286. Ramsay, R.R.; Jones, T.Z.E.; Hynson, R.M.G. Alteration in spectral properties on ligand binding reveals flexibility in monoamine oxidase. Med. Sci. Monit., 2005, 11, SR15-SR20.